ERBB2 and breast adenocarcinoma: Anti-neoplastic cytotoxicity of gemcitabine or gemcitabine-(C4-amide)-[anti-HER2/neu] was increased when they were applied in dual combination with the tubulin/microtubule inhibitor griseofulvin against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations.